ANNAPOLIS – Some institutional investors in PharmAthene, Inc. will purchase about $5.5 million of the company’s common stock and warrants this week. The bio-defense company will use the net proceeds for general corporate purposes such as satisfying existing obligations.
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1323698127.gif)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1270748889.png)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1286484661.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1312923369.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1313587373.gif)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1268857522.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1270748904.png)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1286484732.jpg)